Immunohistochemical Expression of Cyclooxygenase-2 in endometrioid carcinoma

Kavi Kamaran  Abbas; Jalal Ali  Jalal

doi:10.56056/amj.2024.276

Authors

Kavi Kamaran Abbas SHO of Histopathology in Rizgary Hospital, trainee of Histopathology at the Kurdistan higher council of medical specialties (KHCMS), Erbil.
Jalal Ali Jalal Professor of pathology at college of medicine-Hawler medical university, Erbil

DOI:

https://doi.org/10.56056/amj.2024.276

Keywords:

COX-2, Endometrioid carcinoma, Immunohistochemistry

Abstract

Background and objectives: Cyclooxygenase-2 functions as an enzyme which synthesize prostaglandins from Arachidonic acid Cyclooxygenase -2 is one of the important factors in maintaining the endometrium during menstrual cycle. The Aim of this study was to assess expression of Cyclooxygenase-2 in endometrioid carcinoma by immunohistochemistry to explore association between Cyclooxygenase-2 expression and a certain number of clinicopathologic variables.

Methods: A retrospective study was carried out for seventy-eight blocks that were preseved in formalin and embedded in paraffin of endometrioid carcinoma were obtained and randomly selected from a private laboratory in Erbil city during October 2020 to October 2022. COX-2 rabbit monoclonal antibody was used to satin slides obtained from endometrioid carcinoma blocks and the expression was scored by multiplying the number of stained cells by the intensity of staining.

Results: Cyclooxygenase-2 expressed in 15.4% of cases of study cases. It is down-expressed in high grade endometrioid carcinoma while over-expressed in cases with myometrial invasion ?50%. Regarding other clinicopathological parameters like, lymphovascular invasion, tumor stage and lymphnode status, Cyclooxygenase-2 showing down-expression, there is no existence of notable link between the expression of Cyclooxygenase-2 and clinicopathological parameters, including: Age(p=0.197), Tumor grade(p=0.069), Myometrial invasion(p=0.261), Lympho vascular invasion(p=0.516), Lymph node status(p=1000) and Tumor stage(p=0.872).

Conclusion: Cyclooxygenase-2 is expressed in a limited number of endometrioid carcinoma and there is lack of significant association between Cyclooxygenase-2 expression and clinicopathological parameters.

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.Cancer J Clin. 2018;68(6):394-424.

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.

Kehoe S, Bhatla N. FIGO cancer report 2021. Int Journal of Gynecology & Obstetrics. 2021;155(Suppl. 1):5-6.

Abdullah OS, Amin A, Mohamed ZA, Hasan B, Shekha M, Najmuldeen HH, et al. Cancer Incidence in the Kurdistan Region of Iraq: Results of a Seven-Year Cancer Registration in Erbil and Duhok Governorates. Asian Pac J Cancer Prev. 2022;23(2):601-15.

Li M, Li M, Wei Y, Xu H. Prognostic and Clinical Significance of Cyclooxygenase-2 Overexpression in Endometrial Cancer: A Meta-Analysis. Front Oncol. 2020;10:1202.

Talhouk A, McAlpine JN, practice. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016;3:1-12.

McAlpine J, Leon?Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018;244(5):538-49.

Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019;38(1 Suppl 1):S64.

Ma X, Hui Y, Lin L, Wu Y, Zhang X, Liu P. Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak J Med Sci. 2015;31(2):280.

Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, et al. Cyclooxygenase?2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer. 2002;95(4):801-7.

Deng L, Liang H, Han YJFio. Cyclooxygenase-2 and ?-catenin as potential diagnostic and prognostic markers in endometrial cancer. Front Oncol. 2020;10:56.

Berbecka M, Forma A, Baj J, Furtak-Niczyporuk M, Maciejewski R, Sitarz R. A systematic review of the cyclooxygenase-2 (COX-2) expression in rectal cancer patients treated with preoperative radiotherapy or radiochemotherapy. J Clin Med. 2021;10(19):4443.

Kumari P, Sharma I, Saha SC, Srinivasan R, Sharma A, Therapeutics. Promoter methylation status of key genes and its implications in the pathogenesis of endometriosis, endometrioid carcinoma of ovary and endometrioid endometrial cancer. J Cancer Res Ther. 2022;18(Suppl 2):S328-S34.

Ohno S, Ohno Y, Suzuki N, Inagawa H, Kohchi C, Soma G-I, et al. Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res. 2005;25(6A):3679-87.

Ku?mycz O, St?czek P, Therapy. Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome. Cancer Biol Ther. 2020;21(6):486-94.

Lyndin M, Kravtsova O, Sikora K, Lyndina Y, Kuzenko Y, Awuah W, et al. COX2 Effects on endometrial carcinomas progression. Pathol Res Pract. 2022;238:154082.

Li N, Jian W, Zhou T, Gu C, Cai Z, Gan H, et al. Celecoxib inhibits endometrial cancer cells through COX-2-dependent and non-dependent pathways. Int J Clin Exp Med. 2019;12(5):4707-16.

Jamieson A, Huvila J, Chiu D, Thompson EF, Scott S, Salvador S, et al. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death. Mod Pathol. 2023;36(4):100085.

Wang P-H, Yang S-T, Liu C-H, Chang W-H, Lee FK, Lee WL, et al. Endometrial cancer: part I. Basic concept. Taiwan J Obstet Gynecol. 2022;61(6):951-9.

Xiao Y, Luo L, Zhang R. Effect of lentivirus mediated cyclooxygenase-2 gene shorthairpinRNA on invasiveness of endometrial carcinoma. Eur J Gynaecol Oncol. 2015;36(1):44-8.

Nasir A, Boulware D, Kaiser H, Lancaster J, Coppola D, Smith P, et al. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo. 2007;21(1):35-43.

Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98(3):383-9.

Gullo G, Etrusco A, Cucinella G, Perino A, Chiantera V, Laganà AS, et al. Fertility-sparing approach in women affected by stage I and low-grade endometrial carcinoma: an updated overview. Int J Mol Sci. 2021;22(21):11825.

Nobari N, Niknejad N, Poorolajal J, Vaezi M, Nili F, Jahanzad I. Clinicopathologic features and prognostic role of CD3, CD8, and PD-1 positive tumor-infiltrating lymphocytes and the association with COX-2 overexpression in endometrial carcinoma. Int J Cancer Manag. 2020;13(4).

Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 1998;58(14):2929-34.

Uhar?ek P, Research G. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res. 2008;34(5):776-83.